{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:35:52Z","timestamp":1760852152074,"version":"build-2065373602"},"reference-count":101,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.ecl.2004.04.003","type":"journal-article","created":{"date-parts":[[2005,4,18]],"date-time":"2005-04-18T10:53:30Z","timestamp":1113821610000},"page":"595-616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Glitazones and the management of insulin resistance: what they do and how might they be used"],"prefix":"10.1016","volume":"33","author":[{"given":"Daniel","family":"Einhorn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanita R","family":"Aroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert R","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2004.04.003_BIB1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev.med.52.1.239","article-title":"New oral therapies for type 2 diabetes\u2014the thiazolidinediones or insulin sensitizers","volume":"52","author":"Mudaliar","year":"2001","journal-title":"Annu Rev Med"},{"issue":"12","key":"10.1016\/j.ecl.2004.04.003_BIB2","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","article-title":"Banting lecture 1988. Role of insulin resistance in human disease","volume":"37","author":"Reaven","year":"1988","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.ecl.2004.04.003_BIB3","first-page":"237","article-title":"American College of Endocrinology position statement on the insulin resistance syndrome","volume":"9","author":"Einhorn","year":"2003","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.ecl.2004.04.003_BIB4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1467-789X.2001.00045.x","article-title":"Sleep disordered breathing\u2014a new component of syndrome X?","volume":"2","author":"Coughlin","year":"2001","journal-title":"Obes Rev"},{"key":"10.1016\/j.ecl.2004.04.003_BIB5","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","author":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2004.04.003_BIB6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabet Med"},{"key":"10.1016\/j.ecl.2004.04.003_BIB7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1056-8727(01)00159-3","article-title":"Clinical evaluation of plasma high-density lipoprotein subfractions (HDL2, HDL3) in non-insulin-dependent diabetics with coronary artery disease","volume":"15","author":"Bakogianni","year":"2001","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.ecl.2004.04.003_BIB8","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1161\/01.ATV.17.6.1098","article-title":"Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study","volume":"17","author":"Lamarche","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.ecl.2004.04.003_BIB9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0889-8529(05)70029-3","article-title":"Dyslipoproteinemia and diabetes","volume":"27","author":"Garg","year":"1998","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.ecl.2004.04.003_BIB10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9343(97)00027-2","article-title":"Insulin resistance implications for type II diabetes and coronary artery disease","volume":"103","author":"Haffner","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.ecl.2004.04.003_BIB11","unstructured":"Pioglitazone [prescribing information]: Lincolnshire, IL: Takeda; Indianapolis, IN: Elli Lilly; 2002."},{"issue":"5","key":"10.1016\/j.ecl.2004.04.003_BIB12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00019501-200108000-00011","article-title":"The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus","volume":"12","author":"Rosenblatt","year":"2001","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.ecl.2004.04.003_BIB13","doi-asserted-by":"crossref","first-page":"708","DOI":"10.2337\/diacare.25.4.708","article-title":"A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone","volume":"25","author":"Khan","year":"2002","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ecl.2004.04.003_BIB14","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0002-9149(02)02659-0","article-title":"Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus","volume":"90","author":"Freed","year":"2002","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.ecl.2004.04.003_BIB15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2337\/diacare.27.1.41","article-title":"Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes","volume":"27","author":"Lawrence","year":"2004","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ecl.2004.04.003_BIB16","doi-asserted-by":"crossref","first-page":"796","DOI":"10.2337\/diacare.21.5.796","article-title":"Troglitazone decreases the proportion of small dense LDL and increases the resistance of LDL to oxidation in obese subjects","volume":"21","author":"Tack","year":"1998","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.ecl.2004.04.003_BIB17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.7326\/0003-4819-129-2-199807150-00030","article-title":"Troglitazone and small low-density lipoprotein in type 2 diabetes","volume":"129","author":"Hirano","year":"1998","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.ecl.2004.04.003_BIB18","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0149-2918(03)80068-1","article-title":"A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus","volume":"25","author":"Herz","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.ecl.2004.04.003_BIB19","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/S0140-6736(05)63572-6","article-title":"Increase of lipoprotein (a) with troglitazone","volume":"350","author":"Matsumoto","year":"1997","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ecl.2004.04.003_BIB20","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0026-0495(03)00033-7","article-title":"The effect of rosiglitazone on serum lipoprotein (a) levels in Korean patients with type 2 diabetes mellitus","volume":"52","author":"Ko","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.ecl.2004.04.003_BIB21","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2337\/diacare.24.2.408-a","article-title":"Does pioglitazone, like troglitazone, increase serum levels of lipoprotein (a) in diabetic patients?","volume":"24","author":"Nagai","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2004.04.003_BIB22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial","volume":"360","author":"The Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2004.04.003_BIB23","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1161\/01.HYP.36.2.226","article-title":"High triglycerides and low HDL cholesterol and blood pressure and risk of ischemic heart disease","volume":"36","author":"Jeppesen","year":"2000","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.ecl.2004.04.003_BIB24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/sj.jhh.1001444","article-title":"Rosiglitazone reduces urinary albumin excretion in type II diabetes","volume":"17","author":"Bakris","year":"2003","journal-title":"J Hum Hypertens"},{"issue":"12","key":"10.1016\/j.ecl.2004.04.003_BIB25","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1210\/jc.2002-020963","article-title":"Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study","volume":"87","author":"Fullert","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2004.04.003_BIB26","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1056-8727(00)00124-0","article-title":"Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients","volume":"14","author":"Nakamura","year":"2000","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.ecl.2004.04.003_BIB27","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.2337\/diacare.21.12.2135","article-title":"Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy","volume":"21","author":"Imano","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2004.04.003_BIB28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7326\/0003-4819-134-1-200101020-00014","article-title":"Nonhypoglycemic effects of thiazolidinediones","volume":"134","author":"Parulkar","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ecl.2004.04.003_BIB29","first-page":"V67","article-title":"Dysfunction of vascular endothelium in diabetes mellitus","volume":"87","author":"Cohen","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2004.04.003_BIB30","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1172\/JCI117433","article-title":"Insulin-mediated skeletal muscle vasodilatation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release","volume":"94","author":"Steinberg","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ecl.2004.04.003_BIB31","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2337\/diab.43.1.104","article-title":"Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients","volume":"43","author":"McGill","year":"1994","journal-title":"Diabetes"},{"key":"10.1016\/j.ecl.2004.04.003_BIB32","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2337\/diacare.17.8.818","article-title":"Platelet plasminogen activator inhibitor 1 in patients with type 2 diabetes","volume":"17","author":"Jokl","year":"1994","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2004.04.003_BIB33","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2337\/diacare.21.4.649","article-title":"Plasma fibrinogen: a new factor of the metabolic syndrome","volume":"21","author":"Imperatore","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2004.04.003_BIB34","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2337\/diabetes.49.4.633","article-title":"Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects","volume":"49","author":"Kruszynska","year":"2000","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.ecl.2004.04.003_BIB35","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1160\/TH03-06-0384","article-title":"Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones","volume":"91","author":"Zirlik","year":"2004","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.ecl.2004.04.003_BIB36","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1046\/j.1463-1326.2003.00276.x","article-title":"Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes","volume":"5","author":"Harte","year":"2003","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ecl.2004.04.003_BIB37","first-page":"2108","article-title":"Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome","volume":"82","author":"Ehrmann","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2004.04.003_BIB38","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1161\/01.ATV.0000062885.61917.A5","article-title":"Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy","volume":"23","author":"Yki-Jarvinen","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ecl.2004.04.003_BIB39","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2003.04.001","article-title":"The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients","volume":"42","author":"Sidhu","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2004.04.003_BIB40","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1345\/aph.1D203","article-title":"Role of C-reactive protein in cardiovascular disease","volume":"38","author":"Backes","year":"2004","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.ecl.2004.04.003_BIB41","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.amjcard.2003.10.022","article-title":"Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome","volume":"93","author":"Wang","year":"2004","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.1016\/j.ecl.2004.04.003_BIB42","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.2337\/diacare.26.9.2493","article-title":"Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect","volume":"26","author":"Satoh","year":"2003","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.ecl.2004.04.003_BIB43","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2337\/diacare.25.3.542","article-title":"Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes","volume":"25","author":"Chu","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2004.04.003_BIB44","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis: an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ecl.2004.04.003_BIB45","doi-asserted-by":"crossref","first-page":"E1125","DOI":"10.1152\/ajpendo.00430.2002","article-title":"Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats","volume":"284","author":"Iida","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ecl.2004.04.003_BIB46","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2337\/diab.47.1.130","article-title":"Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients","volume":"47","author":"Cominacini","year":"1998","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.ecl.2004.04.003_BIB47","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2337\/diacare.24.2.392","article-title":"Control of vascular cell proliferation and migration by PPAR-gamma","volume":"24","author":"Hsueh","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2004.04.003_BIB48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1161\/01.CIR.101.3.235","article-title":"Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-g activators","volume":"101","author":"Pasceri","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2004.04.003_BIB49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0014-5793(99)00765-6","article-title":"Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells","volume":"454","author":"Murao","year":"1999","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ecl.2004.04.003_BIB50","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1161\/01.RES.85.5.394","article-title":"Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway","volume":"85","author":"Delerive","year":"1999","journal-title":"Circ Res"},{"key":"10.1016\/j.ecl.2004.04.003_BIB51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1056-8727(97)00109-8","article-title":"Effect of troglitazone on fibrinolysis and activated coagulation in patients with non\u2013insulin-dependent diabetes mellitus","volume":"12","author":"Fonseca","year":"1998","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.ecl.2004.04.003_BIB52","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/34184","article-title":"PPAR\u03b3 agonists inhibit production of monocyte inflammatory cytokines","volume":"39","author":"Jiang","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ecl.2004.04.003_BIB53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0002-9440(10)65540-X","article-title":"Macrophages in human atheroma contain PPAR\u03b3: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPAR\u03b3) expression and reduction of MMP-activity through PPAR\u03b3 activation in mononuclear phagocytes in vitro","volume":"153","author":"Marx","year":"1998","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.ecl.2004.04.003_BIB54","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1097-2765(01)00164-2","article-title":"A PPAR\u03b3-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis","volume":"7","author":"Chawla","year":"2001","journal-title":"Mol Cell"},{"key":"10.1016\/j.ecl.2004.04.003_BIB55","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/01.CIR.101.11.1311","article-title":"Expression and function of PPAR\u03b3 in rat and human vascular smooth muscle cells","volume":"101","author":"Law","year":"2000","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ecl.2004.04.003_BIB56","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1161\/01.HYP.0000036396.64769.C2","article-title":"Antiinflammatory and antiarteriosclerotic effects of pioglitazone","volume":"40","author":"Ishibashi","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2004.04.003_BIB57","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1172\/JCI118991","article-title":"Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia","volume":"98","author":"Law","year":"1996","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.ecl.2004.04.003_BIB58","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/0895-7061(95)00393-2","article-title":"Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation","volume":"9","author":"Peuler","year":"1996","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ecl.2004.04.003_BIB59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.ATV.0000124890.40436.77","article-title":"Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus","volume":"24","author":"Sidhu","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ecl.2004.04.003_BIB60","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1210\/jcem.83.5.4932","article-title":"Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes","volume":"83","author":"Minamikawa","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2004.04.003_BIB61","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1210\/jcem.86.7.7810","article-title":"Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes","volume":"86","author":"Koshiyama","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2004.04.003_BIB62","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0735-1097(00)00895-0","article-title":"Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study","volume":"36","author":"Takagi","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2004.04.003_BIB63","first-page":"82","article-title":"Preventive effects of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes","volume":"52","author":"Choi","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.ecl.2004.04.003_BIB64","first-page":"3078","article-title":"Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study","volume":"83","author":"Knochenhauer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2004.04.003_BIB65","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2337\/diacare.22.1.141","article-title":"Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome","volume":"22","author":"Ehrmann","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2004.04.003_BIB66","first-page":"165","article-title":"Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women","volume":"84","author":"Legro","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2004.04.003_BIB67","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2337\/diab.38.9.1165","article-title":"Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome","volume":"38","author":"Dunaif","year":"1989","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.ecl.2004.04.003_BIB68","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1210\/jcem-57-2-356","article-title":"Insulin resistance in nonobese patients with polycystic ovarian disease","volume":"57","author":"Chang","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2004.04.003_BIB69","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1172\/JCI118064","article-title":"Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus","volume":"96","author":"Ehrmann","year":"1995","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.ecl.2004.04.003_BIB70","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0015-0282(02)03111-4","article-title":"Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus","volume":"77","author":"Ovalle","year":"2002","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ecl.2004.04.003_BIB71","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/humrep\/16.9.1995","article-title":"Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome","volume":"16","author":"Norman","year":"2001","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ecl.2004.04.003_BIB72","first-page":"774","article-title":"Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis","volume":"18","author":"Dunaif","year":"1997","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.ecl.2004.04.003_BIB73","first-page":"1626","article-title":"Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial","volume":"86","author":"Azziz","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2004.04.003_BIB74","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1210\/jc.2002-020386","article-title":"Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome","volume":"88","author":"Paradisi","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2004.04.003_BIB75","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0015-0282(02)04843-4","article-title":"Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome","volume":"79","author":"Ghazeeri","year":"2003","journal-title":"Fertil Steril"},{"issue":"3","key":"10.1016\/j.ecl.2004.04.003_BIB76","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.fertnstert.2003.08.024","article-title":"Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome","volume":"81","author":"Belli","year":"2004","journal-title":"Fertil Steril"},{"issue":"3","key":"10.1016\/j.ecl.2004.04.003_BIB77","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/humrep\/deh145","article-title":"Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome","volume":"19","author":"Guido","year":"2004","journal-title":"Hum Reprod"},{"issue":"2","key":"10.1016\/j.ecl.2004.04.003_BIB78","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2174\/1568008033340289","article-title":"AIDS-related insulin resistance and lipodystrophy syndrome","volume":"3","author":"Kino","year":"2003","journal-title":"Curr Drug Targets Immune Endocr Metabol Disord"},{"key":"10.1016\/j.ecl.2004.04.003_BIB79","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1086\/375885","article-title":"Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome","volume":"37","author":"Grinspoon","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.ecl.2004.04.003_BIB80","doi-asserted-by":"crossref","first-page":"908","DOI":"10.2337\/diacare.22.6.908","article-title":"Effect of troglitazone on body fat distribution in type 2 diabetic patients","volume":"22","author":"Mori","year":"1999","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.ecl.2004.04.003_BIB81","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2337\/diacare.22.2.288","article-title":"Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes","volume":"22","author":"Kelly","year":"1999","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.ecl.2004.04.003_BIB82","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00126334-200210010-00006","article-title":"Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study","volume":"31","author":"Gelato","year":"2002","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"issue":"3","key":"10.1016\/j.ecl.2004.04.003_BIB83","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/135965350300800303","article-title":"Rosiglitazone in the treatment of HAART-associated lipodystrophy\u2014a randomized double-blind placebo-controlled study","volume":"8","author":"Sutinen","year":"2003","journal-title":"Antivir Ther"},{"issue":"6","key":"10.1016\/j.ecl.2004.04.003_BIB84","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11938-003-0047-0","article-title":"Treatment of nonalcoholic fatty liver disease","volume":"6","author":"Liangpunsakul","year":"2003","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"5","key":"10.1016\/j.ecl.2004.04.003_BIB85","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1053\/S1542-3565(03)00198-8","article-title":"Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity","volume":"1","author":"Shadid","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.ecl.2004.04.003_BIB86","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.20012","article-title":"A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis","volume":"39","author":"Promrat","year":"2004","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ecl.2004.04.003_BIB87","first-page":"1008","article-title":"Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone","volume":"38","author":"Neuschwander-Tetri","year":"2003","journal-title":"Hepatology"},{"issue":"7 Suppl 2","key":"10.1016\/j.ecl.2004.04.003_BIB88","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1097\/01.ASN.0000070157.96264.13","article-title":"Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish diabetes prevention study: results from a randomized clinical trial","volume":"14","author":"Lindstrom","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.ecl.2004.04.003_BIB89","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2337\/diacare.20.4.537","article-title":"Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study","volume":"20","author":"Pan","year":"1997","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ecl.2004.04.003_BIB90","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"The Diabetes Prevention Program. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"The Diabetes Prevention Program Research Group","year":"2002","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ecl.2004.04.003_BIB91","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","article-title":"Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial","volume":"290","author":"Chiasson","year":"2003","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2004.04.003_BIB92","first-page":"251","article-title":"Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program","volume":"52","author":"The Diabetes Prevention Program Group","year":"2003","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.ecl.2004.04.003_BIB93","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.2337\/diabetes.51.9.2796","article-title":"Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women","volume":"51","author":"Buchanan","year":"2002","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.ecl.2004.04.003_BIB94","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/0091270004263018","article-title":"Preventing type II diabetes mellitus","volume":"44","author":"Prisant","year":"2004","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ecl.2004.04.003_BIB95","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"issue":"7064","key":"10.1016\/j.ecl.2004.04.003_BIB96","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1136\/bmj.313.7064.1040","article-title":"Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study)","volume":"313","author":"Kiechl","year":"1996","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ecl.2004.04.003_BIB97","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1042\/cs1020345","article-title":"Alcohol consumption, the metabolic syndrome and insulin resistance in 58-year-old clinically healthy men (AIR study)","volume":"102","author":"Goude","year":"2002","journal-title":"Clin Sci"},{"issue":"4","key":"10.1016\/j.ecl.2004.04.003_BIB98","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1365-2362.2000.00624.x","article-title":"Alcohol consumption and insulin resistance in young adults","volume":"30","author":"Flanagan","year":"2000","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"10.1016\/j.ecl.2004.04.003_BIB99","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1047-2797(03)00131-5","article-title":"Alcohol consumption and insulin resistance syndrome parameters: associations and evolutions in a longitudinal analysis of the French DESIR cohort","volume":"14","author":"Vernay","year":"2004","journal-title":"Ann Epidemiol"},{"issue":"2","key":"10.1016\/j.ecl.2004.04.003_BIB100","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1164\/rccm.200302-206OC","article-title":"Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome","volume":"169","author":"Harsch","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ecl.2004.04.003_BIB101","doi-asserted-by":"crossref","unstructured":"Lavasani F, et al. Use of either metformin or thiazolidenedione is associated with improved survival among patients with type 2 diabetes from a registry of 16, 203 patients diabetic patients [abstract 810-5]. Presented at the Annual Scientific Session of the American College of Cardiology. New Orleans, March 7\u201310, 2004.","DOI":"10.1016\/S0735-1097(04)92007-4"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852904000386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852904000386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:19:36Z","timestamp":1760174376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852904000386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0889852904000386"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2004.04.003","relation":{},"ISSN":["0889-8529"],"issn-type":[{"type":"print","value":"0889-8529"}],"subject":[],"published":{"date-parts":[[2004,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glitazones and the management of insulin resistance: what they do and how might they be used","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2004.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}